Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0NZY stock hub

LON/0NZY has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0NZYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

825.9M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0NZY

In the news

Latest news · LON/0NZY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E18.4

P25 12.9P50 16.9P75 23.5

Trailing P/E19.4

P25 15.9P50 22.9P75 35.8

ROE20.6

P25 -54.2P50 2.1P75 13.7

ROIC31.4

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0NZY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

240

Groups with data

Currency

EUR

Showing 240 of 240 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Germany
Country code	UK
Employees	1,116
Employees Change	31%
Employees Change Percent	2.86
Enterprise value	EUR 754.8M
Exchange	London Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	DE0005659700
Last refreshed	2026-05-10
Market cap	EUR 825.9M
Price	EUR 15.37
Price currency	EUR
Rev Per Employee	243,857.93x
Sector	Healthcare
Sic	2810
Symbol	lon/0NZY
Website	https://www.ezag.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.15%
EV Earnings	17.74x
EV/EBIT	11.42x
EV/EBITDA	9.35x
EV/FCF	26.72x
EV/Sales	2.8x
FCF yield	3.42%
Forward P/E	18.44x
P/B ratio	3.74x
P/E ratio	19.41x
P/S ratio	3.03x
PE Ratio10 Y	29.23x
PE Ratio3 Y	29.33x
PE Ratio5 Y	36.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.42%
EBITDA Margin	28.7%
FCF margin	10.38%
Gross margin	49.04%
Gross Profit	EUR 133.5M
Gross Profit Growth	6.86%
Gross Profit Growth Q	16.43%
Gross Profit Growth3 Y	12.74%
Gross Profit Growth5 Y	12.07%
Net Income	EUR 42.5M
Net Income Growth	46.54%
Net Income Growth Q	91.02%
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Net Income Growth3 Y	18.54%
Net Income Growth5 Y	18.03%
Pretax Margin	23.33%
Profit Margin	15.63%
Profit Per Employee	EUR 38,118
Profitable Years	13
ROA	10.58
Roa5y	8.24
ROCE	19.73
ROE	20.57
Roe5y	17.72
ROIC	31.43
Roic5y	23.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	27.98%
Cagr15y	15.58%
Cagr1y	-20.99%
Cagr3y	3.8%
Cagr5y	-6.82%
Div CAGR10	13.79%
Div CAGR3	-0.17%
Div CAGR5	2%
EPS Growth	46.48
EPS Growth Q	91.82
EPS Growth Years	1
EPS Growth3 Y	18.37
EPS Growth5 Y	17.82
FCF Growth	-34.41%
FCF Growth Q	-54.18%
FCF Growth3 Y	64.97%
FCF Growth5 Y	3.04%
OCF Growth	-12.27%
OCF Growth Q	-30.12%
OCF Growth10 Y	13.66%
OCF Growth3 Y	19.42%
OCF Growth5 Y	10.82%
Revenue Growth	5.45x
Revenue Growth Q	9.32x
Revenue Growth Quarters	15x
Revenue Growth Years	4x
Revenue Growth3 Y	11.97x
Revenue Growth5 Y	12.11x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.69
Assets	EUR 399.5M
Cash	EUR 112.3M
Current Assets	EUR 214.5M
Current Liabilities	EUR 62.1M
Debt	EUR 39.1M
Debt EBITDA	EUR 0.48
Debt Equity	EUR 0.18
Debt FCF	EUR 1.38
Equity	EUR 221.1M
Interest Coverage	17
Liabilities	EUR 178.4M
Long Term Assets	EUR 185M
Long Term Liabilities	EUR 116.3M
Net Cash	EUR 73.2M
Net Cash By Market Cap	EUR 8.87
Net Cash Growth	33.21%
Net Debt EBITDA	EUR -0.94
Net Debt Equity	EUR -0.33
Net Debt FCF	EUR -2.59
Tangible Book Value	EUR 184.2M
Tangible Book Value Per Share	EUR 2.94
WACC	12.15

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.45
Inventory Turnover	3.54
Net Working Capital	EUR 49.7M
Quick ratio	2.76
Working Capital	EUR 153.7M
Working Capital Turnover	EUR 1.65

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.16%
Dividend Growth	909.07%
Dividend Growth Years	1%
Dividend per share	EUR 0.14
Dividend Years	19
Dividend Yield	0.92%
Ex Div Date	2025-06-19
Last Dividend	EUR 0.14
Payout Frequency	Annual
Payout Ratio	21.39%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,078.08%
1Y total return	-20.97%
200-day SMA	16.33
3Y total return	11.84%
50-day SMA	14.89
50-day SMA vs 200-day SMA	50under200
5Y total return	-29.75%
All Time High	46.92
All Time High Change	-67.24%
All Time High Date	2021-09-10
All Time Low	1.3
All Time Low Change	1,086.87%
All Time Low Date	2009-07-20
ATR	0.44
Beta	1.48
Ch YTD	0.99
High	15.67
High52	23.07
High52 Date	2025-06-30
High52ch	-33.37%
Low	15.37
Low52	13.32
Low52 Date	2026-03-23
Low52ch	15.39%
Ma50ch	3.26%
Price vs 200-day SMA	-5.89%
RSI	54.56
RSI Monthly	46.51
RSI Weekly	48.35
Sharpe ratio	-0.66x
Sortino ratio	-0.79
Total Return	0.76%
Tr YTD	0.99
Tr15y	777.35%
Tr1m	8.16%
Tr1w	2.4%
Tr3m	-0.58%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 66.5M
Operating Income Growth	14.41
Operating Income Growth Q	35.14
Operating Income Growth3 Y	17.49
Operating Income Growth5 Y	18.08
Operating margin	24.42

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	40,959,324%
Net Borrowing	-9,056,016.7
Shares Insiders	0%
Shares Institutions	23.92%
Shares Qo Q	0.43%
Shares Yo Y	0.16%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 28.3M
Average Volume	129,975x
Bv Per Share	3.51
CAPEX	EUR -22.7M
Ch10y	813.8
Ch15y	504.6
Ch1m	8.16
Ch1w	2.4
Ch1y	-21.58
Ch3m	-0.58
Ch3y	-2.91
Ch5y	-40.04
Ch6m	-2.1
Change	-2.54%
Change From Open	-1.73
Close	15.77
Days Gap	-0.82
Depreciation Amortization	11,551,633.2
Dollar Volume	33,153.1
Earnings Date	2026-05-12
EBIT	EUR 66.5M
EBITDA	EUR 78.1M
EPS	EUR 0.68
F Score	8
FCF	EUR 28.3M
FCF EV Yield	3.74x
Financing CF	-17,040,932
Fiscal Year End	December
Founded	1,992
Goodwill	29,912,795.8
Graham Number	8.56064
Graham Upside	-44.3
Income Tax	EUR 20.5M
Investing CF	-22,621,502
Is Primary Listing	0
Last Earnings Date	2026-03-26
Last Report Date	2025-12-31
Last Split Date	2025-08-13
Last Split Type	Forward
Lynch Fair Value	EUR 14.27
Lynch Upside	-7.13
Ma150	15.56
Ma150ch	-1.25%
Ma20	15.15
Ma20ch	1.44%
Net CF	9,132,000
Next Earnings Date	2026-05-12
Open	15.64
P FCF Ratio	29.23
P OCF Ratio	16.21
Payment Date	2025-06-23
Position In Range	0
Ppne	117,238,609.7
Price Date	2026-05-08
Price EBITDA	EUR 10.57
Ptbv Ratio	4.48
Relative Volume	0.02x
Revenue	272,145,450x
Tax By Revenue	7.54x
Tax Rate	32.34%
Tr6m	-2.1%
Volume	2,157
Z Score	5.6

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

LON/0NZY dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.9%

$0.14 annual per share

Payout ratio

+21.4%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+2.0%

1 consecutive years of growth

Total shareholder yield

+0.8%

Next ex-dividend date: 2025-06-19

Performance

LON/0NZY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0NZY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+23.9%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.2%

Negative means the company is buying back shares.

Technical

LON/0NZY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.6

Neutral momentum band

Price vs 200-day MA

-5.9%

50/200-day relationship not available

Beta (5Y)

1.48

More volatile than the market

Sharpe ratio

-0.66

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0NZY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0NZY stock rating?

lon/0NZY is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0NZY analysis?

The full report lives at /stocks/lon/0NZY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0NZY?

The latest report frames lon/0NZY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0NZY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.